Market News AIOpen the app

ALLR stock news · Allarity Therapeutics

Stories about Allarity Therapeutics (ALLR) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ALLR

Follow Allarity Therapeutics (ALLR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALLR
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 9:07 AM ET · Trial

    Allarity Therapeutics is adding three groups of ovarian cancer patients to its Phase 2 trial for stenoparib.

    Good for ALLR

    Allarity is expanding its stenoparib study to 3 ovarian cancer groups. The wider test is favorable for development, but the added groups have no reported results yet.

  2. Oct 1, 2026, 8:01 AM ET · Market

    Allarity Therapeutics, Inc. shares news about its drug technology and research progress.

    Good for ALLR

    Allarity Therapeutics said its drug-response technology, patents, and lab capabilities have advanced. This supports stenoparib development and could open partnership opportunities, a positive sign.

  3. Sep 29, 2026, 8:15 AM ET · Market

    Allarity Therapeutics, Inc. says it is expanding its lab facilities.

    Neutral

    Allarity expanded its lab work to include proteomics and cell line research. The filing gives no results or business outcomes, so this news does not change its outlook.

  4. Sep 14, 2026, 12:30 PM ET · Market

    Allarity Therapeutics, Inc. says its subsidiary is planning to go public.

    Neutral

    Allarity said a newly formed SPAC filed an S-1 to offer units. That filing alone does not change how we read Allarity.